Topics

vaccine systemic and virological concerns

vaccines
"COVID-19 Vaccines” for Children in the UK: A Tale of Establishment Corruption
A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19
A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge
A GMO Experiment on Two-Thirds of the World’s Population: Reaction to Ulrich’s Commentary on Lee and Broudy
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
A review of neurological side effects of COVID-19 vaccination
A web‑based genome‑wide association study reveals the susceptibility loci of common adverse events following COVID‑19 vaccination in the Japanese population
ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Anaphylaxis-Induced Acute Coronary Syndrome Following Covid-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches
Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway
Antibody-dependent enhancement
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections
Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
Comirnaty Facts: Mechanisms of action and damage potential
Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May – November 2021
COVID-19 Vaccine: Critical Questions with Complicated Answers
Current state of knowledge on the excretion of mRNA and spike produced by anti-COVID-19 mRNA vaccines; possibility of contamination of the entourage of those vaccinated by these products
Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019
Doctors and Scientists Write to the European Medicines Agency, Warning of COVID-19 Vaccine Dangers for a Third Time
Emerging Vaccine-Breakthrough SARS-CoV-2 Variants
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients
Expert testimony of Dr. Christina Parks, PhD
Fauci on Antibody Dependent Enhancement (ADE)
FDA Briefing Document - Moderna COVID-19 Vaccine
FDA Briefing Document: Vaccines and Related Biological Products Advisory Committee Meeting
Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023
Global burden of vaccine-associated kidney injury using an international pharmacovigilance database
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures
Incidence and management of the main serious adverse events reported after COVID-19 vaccination
Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?
Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease
Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs
Interview excerpt with Luc Montagnier (2008 Nobel Prize in Medicine)
Interview with Dr. Robert Malone, inventor of some important mRNA-vaccine technology
Letter to U.S. Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee in response to “Request for Comments related to consideration of vaccines against SARS-CoV-2”
Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America
Open Letter and Notice of Liability from Doctors and Scientists to the EMA and the Members of the European Parliament Regarding COVID-19 Vaccination
Open Letter to the World Health Organization
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection
Potential Conscientious Objection to mRNA Technology as Preventive Treatment for COVID-19
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
Reports of acute adverse events in mRNA COVID‑19 vaccine recipients after the first and second doses in Japan
Review of COVID-19 Vaccines and the Risk of Chronic Adverse Events Including Neurological Degeneration
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
907